Cheryl L. Cohen
Director/Board Member bei CELLDEX THERAPEUTICS, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Cheryl L.
Cohen founded CLC Consulting LLC in 2008, where she worked as President from 2008 to 2011.
Ms. Cohen also currently works at Aerpio Therapeutics, Inc., as Director from 2018, Celldex Therapeutics, Inc., as Independent Director, and ImmunityBio, Inc., as Lead Independent Director from 2019.
Ms. Cohen also formerly worked at LadRx Corp., as Independent Director from 2015 to 2016, Protein Sciences Corp., as Director from 2014 to 2017, NantKwest, Inc., as Independent Director, MEI Pharma, Inc., as Independent Non-Executive Director from 2020 to 2022, Vital Therapies, Inc., as Independent Director from 2015 to 2019, Aerpio Pharmaceuticals, Inc., as Independent Director from 2018 to 2021, Eledon Pharmaceuticals, Inc., as Independent Director from 2015 to 2020, Ignyte Acquisition Corp., as Independent Director, Tokai Pharmaceuticals, Inc., as Independent Director from 2015 to 2020, Centocor, Inc., as Vice President-Rheumatology Franchise from 1998 to 2007, Johnson & Johnson, as Vice President-Rheumatology Franchise, Solvay Pharmaceuticals, Inc., as Principal in 1998, Health Care Systems, Inc., as Vice President-Strategic Commercial Group from 2007 to 2008, Medivation LLC (California), as Chief Commercial Officer from 2011 to 2014, and Janssen Biotech, Inc., as Vice President-Rheumatology Franchise from 1998 to 2007.
Ms. Cohen received her undergraduate degree from Saint Joseph College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IMMUNITYBIO INC
0,03% | 13.09.2023 | 200 617 ( 0,03% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Cheryl L. Cohen
| Unternehmen | Position | Beginn |
|---|---|---|
| IMMUNITYBIO, INC. | Director/Board Member | 01.06.2019 |
| CELLDEX THERAPEUTICS, INC. | Director/Board Member | 16.06.2022 |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Director/Board Member | 01.06.2018 |
Ehemalige bekannte Positionen von Cheryl L. Cohen
| Unternehmen | Position | Ende |
|---|---|---|
| MEI PHARMA, INC. | Director/Board Member | 06.12.2022 |
| AERPIO PHARMACEUTICALS | Director/Board Member | 26.08.2021 |
| ELEDON PHARMACEUTICALS, INC. | Director/Board Member | 30.06.2020 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Director/Board Member | 01.06.2020 |
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Director/Board Member | 12.04.2019 |
Ausbildung von Cheryl L. Cohen
| Saint Joseph College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| LADRX CORPORATION | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| ELEDON PHARMACEUTICALS, INC. | Health Technology |
| IMMUNITYBIO, INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Centocor, Inc.
 Centocor, Inc. Medical SpecialtiesHealth Technology Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA. | Health Technology |
Protein Sciences Corp.
 Protein Sciences Corp. BiotechnologyHealth Technology Protein Sciences Corp. engages in developing and manufacturing recombinant human and veterinary vaccines, therapeutics and diagnostics. The firm develops vaccines for influenza, SARS and other diseases. The company was founded by Mark A. Cochran and Franklin Volvovitz in 1983 and is headquartered in Meriden, CT. | Health Technology |
NantKwest, Inc.
 NantKwest, Inc. BiotechnologyHealth Technology NantKwest, Inc. engages in the research and development of immunotherapies. It uses natural killer cells to treat cancer, infectious diseases, and inflammatory diseases. The company was founded by Gary N. Keller and Hans Georg Klingemannon October 7, 2002 and is headquartered in San Diego, CA. | Health Technology |
Aerpio Therapeutics, Inc.
Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Health Technology |
Solvay Pharmaceuticals, Inc.
 Solvay Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Solvay Pharmaceuticals, Inc manufactures pharmaceutical products. The company produces therapies for cardi-metabolic, gastroenterological, and neurological disorders. Its brands include Androgel, Klonopin, and ACEON drugs. Solvay Pharmaceuticals was founded by Ernest Solvay in 1863 and is located in Marietta, GA. | Health Technology |
Health Care Systems, Inc.
 Health Care Systems, Inc. Packaged SoftwareTechnology Services Health Care Systems, Inc. provides robust physician order entry and medication management solutions. The private company is based in Montgomery, AL. The CEO of the company is Erwin Cablayan. | Technology Services |
Vital Therapies, Inc.
Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Health Technology |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Medivation LLC engages in the development and commercialization of novel therapies to treat serious diseases for which there are limited treatment options. The company was founded by Clarence Patrick Machado and David T. Hung in 2004 and is headquartered in San Francisco, CA. | Health Technology |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
Janssen Biotech, Inc.
 Janssen Biotech, Inc. Pharmaceuticals: MajorHealth Technology Janssen Biotech, Inc. engages in the development and marketing of prescription drugs. The company is headquartered in Horsham, PA. | Health Technology |
| CLC Consulting LLC | |
Aerpio Pharmaceuticals, Inc.
 Aerpio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Pharmaceuticals Inc. is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. The firm's product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 16, 2007 and is headquartered in Cincinnati, OH. | Health Technology |
Ignyte Acquisition Corp.
 Ignyte Acquisition Corp. Financial ConglomeratesFinance Ignyte Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The company was founded on August 6, 2020 and is headquartered in New York, NY. | Finance |
